Cargando…

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial

Major limitations of pulmonary arterial hypertension (PAH) drug trials include the small number of enrolled patients, short term follow up (12-16 weeks), and lack of morbidity and mortality primary endpoints. The recently published SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary...

Descripción completa

Detalles Bibliográficos
Autor principal:	Said, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2014
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220429/ https://www.ncbi.nlm.nih.gov/pubmed/25405173 http://dx.doi.org/10.5339/gcsp.2014.20

Ejemplares similares

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension
por: Said, Karim
Publicado: (2015)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
por: Di Scala, Lilla, et al.
Publicado: (2022)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Radial artery as a second conduit gains momentum: The RAPCO trial
por: Simry, Walid, et al.
Publicado: (2021)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Off-pump coronary artery bypass grafting (OPCABG): the beginning of the end?
por: Taggart, David
Publicado: (2013)

FAME 2: Reshaping the approach to patients with stable coronary artery disease
por: ElGuindy, Ahmed M.
Publicado: (2015)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

PCI versus CABG in patients with complex coronary artery disease: Time for reconciliation?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

Overview of trials from AHA 2021
por: Gergis, Michael, et al.
Publicado: (2021)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
por: Wagdy, Kerolos, et al.
Publicado: (2020)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

Transfusion Indication Threshold Reduction (TITRe2) trial: When to transfuse and what to give?
por: Afifi, Ahmed, et al.
Publicado: (2015)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

CTS Trials Network: A paradigm shift in the surgical treatment of moderate ischemic mitral regurgitation?
por: Afifi, Ahmed
Publicado: (2015)

Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
por: Suwaidi, Jassim Al
Publicado: (2016)

The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
por: Bouhout, Ismail, et al.
Publicado: (2019)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains!
por: Yacoub, Magdi, et al.
Publicado: (2014)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
por: Yacoub, Magdi H, et al.
Publicado: (2013)

Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE
por: Raynaud, Christophe M., et al.
Publicado: (2013)

Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy
por: Kotit, Susy
Publicado: (2023)

Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials
por: Hassan, Mohamed
Publicado: (2014)

CTS trials network: Rate control vs rhythm control for atrial fibrillation after cardiac surgery - Do bitter pills have blessed effects?
por: Afifi, Ahmed
Publicado: (2016)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

Is there an increased cardiovascular risk in metabolically healthy obese individuals? Lessons from the HUNT (Nord-Trøndelag Health) study
por: Al Suwaidi, Jassim
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ed6bbd38pvmaduj7a76a3f32iq